In clinical trials, vaccinia virus has been used to express gp350, EBNA1, and LMP2 to prevent EBV infection [45] or the treatment of NPC [46], indicating that it is a safe and effective platform for antigen delivery and worth further exploration. The gene discussed is PSMB9; the disease is nasopharyngeal carcinoma.